Novel method of treatment

A method of treating a bacterial infection in a human in need thereof which method comprises administering to said human a dosage of a therapeutically effective amount of amoxycillin in the range 1400 to 1900 mg, at dosage regimen interval of about 12 h, such that the dosage regimen provides a mean plasma concentration of amoxycillin of 4 μg/mL for at least 4.4 h, and a mean maximum plasma concentration (Cmax) of amoxycillin of at least 12 μg/mL.

An immediate release pharmaceutical formulation comprising from 950 to 1300 or 1900 to 2600 mg amoxycillin, in combination with pharmaceutically acceptable excipients or carriers.

A modified release pharmaceutical formulation comprising an immediate release phase and a slow release phase;

• the immediate release phase comprising a first part of amoxycillin formulated with pharmaceutically acceptable excipients which allows for immediate release of the first part of amoxycillin, to form an immediate release phase, and the slow release phase comprising a second part of amoxycillin formulated with a release modifying pharmaceutically acceptable excipient, to form a slow release phase.

A pharmaceutical formulation comprising 1000 mg±5% amoxycillin, in combination with pharmaceutically acceptable excipients or carriers.

A pharmaceutical formulation comprising amoxycillin in which amoxycillin is provided as a mixture of amoxycillin trihydrate and sodium amoxycillin in a ratio of from 3:1 to 1:3.

A pharmaceutical formulation comprising a pharmaceutically acceptable soluble salt of amoxycillin in a slow release phase which further comprises a release retarding excipient which is a pharmaceutically acceptable organic acid present in a molar ratio of from 100:1 to 1:10 (amoxycillin salt to organic acid).

A kit comprising an immediate release formulation comprising amoxycillin, and a slow release formulation comprising amoxycillin (and no potassium clavulanate).

Compacted granules for use in a pharmaceutical formulation comprising amoxycillin, a diluent/compression aid, and an organic acid (if amoxycillin is present as a soluble salt thereof) or a release retarding polymer or a mixture thereof.

Compacted granules for use in a pharmaceutical formulation comprising sodium amoxycillin, microcrystalline cellulose, and an organic acid or a release retarding polymer or a mixture thereof.